Nafamostat doses for dialysis blood thinning in ICU
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You are in the ICU and need continuous kidney dialysis (CRRT) for more than 24 hours.
- Normal blood clotting test results (INR ≤ 1.5, fibrinogen ≥ 1.5, APTT ≤ 45 seconds).
- Platelet count of at least 50.
- BMI between 18.5 and 25.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different blood-thinning methods used during continuous kidney-support treatment (CRRT) for patients who have developed severe kidney injury due to sepsis. The goal is to see which method works better and is safer for patients in this critical condition.
This study tests different doses of a continuous blood-filtering treatment for critically ill patients with sudden kidney failure. It may help doctors find the best dose to improve outcomes.
This study tests whether a specific blood-thinning method using citrate works safely and effectively in critically ill patients whose kidneys have suddenly stopped working and need a special filtering machine. Researchers want to confirm that this approach prevents dangerous blood clots while keeping patients safe.
This trial tests a new medicine called nafamostat to prevent blood clots during continuous dialysis (CRRT), for people who are at high risk of bleeding or can't take heparin.
This trial tests a medication called nafamostat mesilate to help control blood clotting problems caused by severe infections (sepsis). It may be an option for people with sepsis who are at risk of bleeding but do not have active bleeding.
This pilot study tests whether nafamostat is safe for people on hemodialysis who have a high risk of bleeding. It may help clinicians find safer ways to manage blood clotting medicines during dialysis.
Hear when a new Continuous Renal Replacement Therapy (CRRT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.